Clinical study of immunotherapy for unresectable advanced pancreatic cancer.
Phase 1
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000001135
- Lead Sponsor
- Tokyo Medical University Hospital
- Brief Summary
no significant different
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
patients who have: uncontrolled infections; active autoimmune diseases; serious cardiac disease, and who have received continuous systemic steroids.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical responses/Safety
- Secondary Outcome Measures
Name Time Method immune response